Summit Therapeutics' novel narrow-spectrum antibiotic ridinilazole (SMT19969) is highly effective in reducing recurrence in Clostridium difficile infections (CDI), and could address a major unmet need in the treatment of the disease, suggest Phase II data due to be presented at the ECCMID meeting in Amsterdam in April.
The data from the 100-patient CoDIFy study exceeded the expectations of the company and have excited experts in the field,...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
